Cargando…

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study

Objectives: We aimed to evaluate the drug retention rate and safety of secukinumab (SEC) in patients with axial spondyloarthritis (AxSpA) and psoriatic arthritis (PsA) in a real clinical setting. Methods: This multicenter retrospective observational study included all AxSpA and PsA patients who rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alonso, Sara, Villa, Ignacio, Fernández, Sabela, Martín, José L., Charca, Lilyan, Pino, Marina, Riancho, Leyre, Morante, Isla, Santos, Monserrat, Brandy, Anahy, Aurrecoechea, Elena, Carmona, Loreto, Queiro, Rubén
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187784/ https://www.ncbi.nlm.nih.gov/pubmed/34124110 http://dx.doi.org/10.3389/fmed.2021.679009

Ejemplares similares

A comparison of disease impact according to the cardiometabolic risk profile in psoriatic arthritis
por: Queiro, Rubén, et al.
Publicado: (2021)

Non-Physical Disease Facets in Spondyloarthritis: An ASAS Health Index-Based Analysis between Psoriatic Arthritis and Axial Spondyloarthritis
por: Queiro, Rubén, et al.
Publicado: (2022)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016)

Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Interleukin-17–targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile
por: Queiro, Rubén, et al.
Publicado: (2023)

A Review of the Use of Secukinumab for Psoriatic Arthritis
por: Patel, Nupur U., et al.
Publicado: (2017)

Correction to: Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis
por: Gentileschi, Stefano, et al.
Publicado: (2020)

Changes in metabolic parameters in psoriatic patients treated with secukinumab
por: Wang, Hsuan Ning, et al.
Publicado: (2020)

Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis
por: Kirby, Colm, et al.
Publicado: (2021)

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence
por: Braun, Jürgen, et al.
Publicado: (2021)

Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
por: Sivera, Francisca, et al.
Publicado: (2023)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
por: Mease, Philip, et al.
Publicado: (2016)

Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
por: Buchanan, Vanessa, et al.
Publicado: (2018)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019)

Cutaneous Vasculitis with Gut Involvement During Secukinumab Treatment for Psoriatic Arthritis
por: CHELLI, Clara, et al.
Publicado: (2020)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
por: Alegre-Sancho, Juan José, et al.
Publicado: (2023)

Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA
por: Gaffney, Karl, et al.
Publicado: (2023)

Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: A Pilot Study
por: Damiani, Giovanni, et al.
Publicado: (2019)

Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab
por: Herrero-Moyano, María, et al.
Publicado: (2018)

Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2020)

Abrupt Development of Esophageal Candidiasis after Secukinumab Treatment in a Psoriatic Patient
por: Kang, Hyun Jin, et al.
Publicado: (2021)

New-Onset Collagenous Colitis in a Patient With Psoriatic Arthritis: Can It Be Secukinumab?
por: Obeidat, Adham E, et al.
Publicado: (2021)

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
por: Gisondi, Paolo, et al.
Publicado: (2022)

Successful treatment with secukinumab in an HIV‐positive psoriatic patient after failure of apremilast
por: Romita, Paolo, et al.
Publicado: (2022)

Real-life effectiveness and safety of secukinumab in axial spondyloarthritis: a single-center study
por: Sun, Yuankai, et al.
Publicado: (2022)

Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
por: Moreno-Ramos, Manuel José, et al.
Publicado: (2022)

A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2023)

Granuloma Annulare in the Setting of Secukinumab
por: Clark, Matthew L., et al.
Publicado: (2018)

Secukinumab in Generalized Pustular Psoriasis
por: Madanagobalane, Shraddha
Publicado: (2018)

Secukinumab on Refractory Lupus Nephritis
por: Costa, Rita, et al.
Publicado: (2021)

Secukinumab-Induced Lymphocytic Colitis
por: Gandu, Siva Santosh Kumar, et al.
Publicado: (2022)

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
por: Elewski, Boni E., et al.
Publicado: (2021)

Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan
por: Fujita, Hideki, et al.
Publicado: (2020)

A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Correction to: Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
por: Moreno-Ramos, Manuel José, et al.
Publicado: (2022)

Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years
por: Aparicio, María, et al.
Publicado: (2021)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
por: Coates, Laura C., et al.
Publicado: (2019)

Efficacy and safety of secukinumab in patients with psoriatic arthritis: A meta-analysis of different dosing regimens
por: Zhang, Kai-Lin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_glmgbno1rp3atv09ob93uc1ccd